Navigation Links
Kensey Nash Receives FDA 510(k) Clearance for New Safe-Cross(R) Vessel Wall Detection Technology
Date:2/20/2008

EXTON, Pa., Feb. 20 /PRNewswire-FirstCall/ -- Kensey Nash Corporation (Nasdaq: KNSY) today announced that it has received 510(k) clearance for an important vessel wall detection technology from the U.S. Food and Drug Administration, designed to enhance the guidance provided by the Safe-Cross(R) RF CTO System. The Safe-Cross System combines a forward-looking guidance system and radio frequency (RF) energy to safely cross and recanalize chronic total occlusions in the coronary and peripheral arteries.

The clearance allows Kensey Nash to incorporate a new interferometer with greater dynamic range into the Safe-Cross console, an important element of the System involved in vessel wall detection. The advanced technology will allow the System to sense the vessel wall farther in advance. Earlier vessel wall detection should provide the physician operator with more options to redirect the wire while crossing a chronic total occlusion.

"We believe this will be a very significant advancement for our Safe-Cross technology," commented Douglas G. Evans, Chief Operating Officer of Kensey Nash Corporation. "While the mechanism of detection is identical to our current Safe-Cross System, the new high dynamic range interferometer should allow a physician to detect the vessel wall sooner, and to have more flexibility to make appropriate adjustments with the direction of the wire. We believe this will be a welcome advancement in the treatment of challenging CTO lesions," he concluded.

Safe-Cross consoles incorporating the new technology will undergo a period of user evaluations prior to broader market introduction. This new technology has also been submitted in a design dossier for CE Mark approval, expected later this year. Separately, K
'/>"/>

SOURCE Kensey Nash Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Kensey Nash to Present at the Canaccord Adams Small-Cap Orthopedics Conference
2. Kensey Nash to Participate in the Sidoti Fifth Annual Palm Beach Emerging Growth Institutional Investor Forum Conference
3. Kensey Nash to Participate in the RBC Capital Markets Healthcare Conference
4. Kensey Nash to Present at the Sidoti Sixth Annual West Coast Emerging Growth Institutional Investor Forum Conference
5. Barr Receives Final Approval for Generic Mirapex(R) Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg & 1.5mg
6. Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA Seal Of Approval
7. Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management
8. BioSpace.com Receives WEDDLEs 2008 Users Choice Award for Best Job Boards
9. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
10. AGA Medical Corporation Receives European CE Mark Approval for the AMPLATZER(R) Duct Occluder II
11. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Pulmonary Heart Valves
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 2015 The winners of awards for ... by the Global Supply Chain Resiliency Council ... on Wednesday, February 25th, 2015, at the Hyatt Regency ... to bring together supply chain risk management and resiliency ... professional discipline through opportunities to collaborate, develop and share ...
(Date:3/3/2015)...  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or ... Expert Opinion on Biological Therapy , Dr. Michael ... , at the Henry Ford Hospital in ... (TB4) has the capacity to promote CNS and peripheral ... leading to neurological recovery in each case.  They pointed ...
(Date:3/3/2015)... CARLOS, Calif. , March 3, 2015  Rosa ... expertise in drug-disease modeling and simulation research, today announced ... the 2015 American Society for Clinical Pharmacology and Therapeutics ... March 3-7 2015.   Logo - ... and Rosa will present a poster describing a quantitative ...
(Date:3/3/2015)... Kindred Biosciences, Inc. (NASDAQ: KIN ), ... of pets, announced today that it will release its fourth ... after the market close. The Company will host a conference ... Interested parties may access the call by dialing toll-free ... using conference ID 98449349.  The call will ...
Breaking Biology Technology:Global Supply Chain Resiliency Council Names Award Winners 2Global Supply Chain Resiliency Council Names Award Winners 3Global Supply Chain Resiliency Council Names Award Winners 4Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 2Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 3
... INTRODUCTION , ... which hydrolyze β -lactam antibiotics. The majority of β -lactamases produced ... to combating the serine active site β -lactamases is the use ... a β -lactam antibiotic 4 . , There is also a ...
... McGown, Ph.D. and Anna Lam, B.S., ... Molecular Devices Corporation, 8/99 , , INTRODUCTION ... use synthetic chromogenic or flu-orogenic peptide substrates. Enzyme selectivity is ... catalytic site of a particular enzyme. The chromophore or fluorophore ...
... Vronique Brechler, David Handfield, Martin Boissonneault, Esther Tremblay, ... Introduction , ... led to an unprecedented increase in both the number of compounds ... automated liquid handling and microplate assay systems has helped to meet ...
Cached Biology Technology:A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 2A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 3A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 4A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 5A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 6Fluorometric Protease Assays in the SpectraMax Gemini Microplate Spectrofluorometer: Example Using Caspase3 (MaxLine Application Note #35) 2Fluorometric Protease Assays in the SpectraMax Gemini Microplate Spectrofluorometer: Example Using Caspase3 (MaxLine Application Note #35) 3Fluorometric Protease Assays in the SpectraMax Gemini Microplate Spectrofluorometer: Example Using Caspase3 (MaxLine Application Note #35) 4Fluorometric Protease Assays in the SpectraMax Gemini Microplate Spectrofluorometer: Example Using Caspase3 (MaxLine Application Note #35) 5Fluorometric Protease Assays in the SpectraMax Gemini Microplate Spectrofluorometer: Example Using Caspase3 (MaxLine Application Note #35) 6Development of Radioligand Binding Assays for the Motilin Receptor Using ScreenReady Targets. 2Development of Radioligand Binding Assays for the Motilin Receptor Using ScreenReady Targets. 3Development of Radioligand Binding Assays for the Motilin Receptor Using ScreenReady Targets. 4Development of Radioligand Binding Assays for the Motilin Receptor Using ScreenReady Targets. 5
(Date:2/11/2015)... February 11, 2015 ... "Access Control Market by Product (Cards and Readers, Biometrics, ... Defense, Government, Industrial, Healthcare, Education) and By Geography - Global ... MarketsandMarkets, the Access Control Market is expected ... at a CAGR of 10.6% between 2014 ...
(Date:2/5/2015)... 5, 2015  Marken is starting its 35 th ... launched a new marketing campaign to solidify its place ... new campaign focuses on First as a ... The first headline in the series, ... with its client,s priorities. Marken recognizes the need to ...
(Date:2/5/2015)... -- New Market Research Reports Title Global ... 2020 has Been Added to GrandViewReseach.com Report Database ... reach USD 5.10 billion by 2020, according to a ... help identify the site of tissue damage in case ... in medical imaging applications. They have been extensively used ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... book titles to real estate developments, it,s easier to find ... it. That,s why a Kansas State University geographer is ... who might be trying to work toward it. Her goal ... have to make decisions about what to sustain with the ...
... WASHINGTONThe Wilson Center,s Synthetic Biology project recently ... One will support a Transatlantic Exploratory Workshop on ... and Policy, and the other will support research ... explore emerging issues in synthetic biology. The ...
... Ariz. (Sept. 22, 2009) TGen Clinical Research Services ... clinical trial for a drug designed to combat adrenocortical ... the adrenal glands. TCRS is a strategic alliance ... Healthcare. Other than surgery, the only treatment for ...
Cached Biology News:K-State geographer working to clarify what sustainability really means to rural decision-makers 2Revolutionary drug could be new hope for adrenal cancer patients 2Revolutionary drug could be new hope for adrenal cancer patients 3
IMAGEQUANT 400 WKSTN, 1 EA. Category: ImageQuant CCD Imagers....
PAb to Hu-IFN-Alpha/Beta R2 [(IFNAR2) CD118], Rabbit Serum, neutralizing Binds to but does not neutralize human interferon alpha/beta receptor...
ANTI MYCOBACTERIUM TUBERCULOSIS...
ImageQuant 400, 1 EA. Category: ImageQuant CCD Imagers....
Biology Products: